HC Wainwright reaffirmed their buy rating on shares of Scribe Therapeutics (NASDAQ:SCTX – Free Report) in a report published on Thursday,Benzinga reports. They currently have a $60.00 price target on the stock. HC Wainwright also issued estimates for Scribe Therapeutics’ Q4 2026 earnings at ($0.55) EPS, FY2026 earnings at ($4.60) EPS, Q1 2027 earnings at ($0.58) EPS, Q2 2027 earnings at ($0.61) EPS, Q3 2027 earnings at ($0.71) EPS, Q4 2027 earnings at ($0.80) EPS and FY2027 earnings at ($2.71) EPS.
Other analysts also recently issued research reports about the company. Leerink Partners started coverage on Scribe Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 price objective on the stock. Weiss Ratings started coverage on Scribe Therapeutics in a research note on Tuesday, October 20th. They set a “sell (e-)” rating for the company. Wall Street Zen raised Scribe Therapeutics to a “hold” rating in a research note on Saturday, August 1st. Wells Fargo & Company started coverage on Scribe Therapeutics in a report on Tuesday, August 18th. They set an “overweight” rating and a $60.00 target price on the stock. Finally, Zacks Research upgraded shares of Scribe Therapeutics to a “hold” rating in a research report on Tuesday, September 1st. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Scribe Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $51.75.
Read Our Latest Analysis on Scribe Therapeutics
Scribe Therapeutics Trading Down 8.7%
Shares of NASDAQ:SCTX opened at $12.07 on Thursday. The stock has a 50 day moving average of $19.56. The firm has a market cap of $228.61 million and a price-to-earnings ratio of -1.04. Scribe Therapeutics has a twelve month low of $12.00 and a twelve month high of $39.60.
Scribe Therapeutics (NASDAQ:SCTX – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.26). The company had revenue of $1.64 million for the quarter. Equities analysts forecast that Scribe Therapeutics will post -4.60 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of SCTX. Goldman Sachs Group Inc. bought a new stake in shares of Scribe Therapeutics during the 3rd quarter worth $398,000. State Street Corp acquired a new stake in shares of Scribe Therapeutics during the third quarter worth $3,150,000. Baker BROS. Advisors LP acquired a new stake in shares of Scribe Therapeutics during the third quarter worth $12,675,000. Finally, RA Capital Management L.P. acquired a new stake in shares of Scribe Therapeutics during the third quarter worth $33,169,000.
Scribe Therapeutics Company Profile
Scribe Therapeutics is a biotechnology company focused on developing CRISPR-based gene-editing technologies and potential genetic medicines. Its platform uses engineered CRISPR systems designed to make targeted changes to DNA, with research aimed at applications across multiple disease areas. Founded in 2017 and based in Alameda, California, the company has pursued research and development collaborations with pharmaceutical companies, including Sanofi and Biogen. Scribe Therapeutics is privately held; I could not verify a Nasdaq listing under the symbol SCTX.
Further Reading
- Five stocks we like better than Scribe Therapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
